Bristol-Myers Squibb Company · NYSE (us_market)
Healthcare · Drug Manufacturers - General · United States
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-03-12$54.40 RISE2024-07-05$39.66 PEAK2024-09-30$51.74 202d | -27.1% 115d | Missed | Missed | — | — | +30.5% 87d | Missed |
DROP2024-03-12$54.40 RISE2024-05-30$40.25 PEAK2024-07-26$50.45 136d | -26.0% 79d | Missed | Missed | — | — | +25.3% 57d | Missed |
DROP2024-03-12$54.40 RISE2024-05-29$40.25 PEAK2024-07-26$50.45 136d | -26.0% 78d | Missed | Missed | — | — | +25.3% 58d | Missed |
DROP2022-06-27$79.98 RISE2022-08-29$66.75 PEAK2022-11-08$79.98 134d | -16.5% 63d | Missed | Missed | — | — | +19.8% 71d | Missed |
DROP2021-08-03$69.31 RISE2021-11-30$53.63 PEAK2022-02-25$68.80 206d | -22.6% 119d | Missed | Missed | — | — | +28.3% 87d | Missed |
DROP2021-08-03$69.31 RISE2021-10-27$56.49 PEAK2022-01-11$65.48 161d | -18.5% 85d | Missed | Missed | — | — | +15.9% 76d | Missed |
DROP2020-02-06$67.10 RISE2020-06-15$55.10 PEAK2020-08-12$63.64 188d | -17.9% 130d | Missed | Missed | — | — | +15.5% 58d | Missed |
DROP2020-01-22$67.43 RISE2020-03-23$46.40 PEAK2020-05-15$64.09 114d | -31.2% 61d | Missed | Missed | — | — | +38.1% 53d | Missed |
Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced treatment.
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.
Bristol-Myers Squibb Company (NYSE:BMY) is one of the 12 Most Undervalued Stocks to Invest In. On May 20, 2026, Bristol-Myers Squibb Company (NYSE:BMY) announced a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions. Bristol Myers Squibb said the collaboration moves its AI use beyond conversational tools […]
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has become one of the most-owned dividend funds in the country, with $71.6 billion in assets and a 0.06% expense ratio. SCHD currently yields roughly 3.3% and has delivered a 20% year-to-date price return on top of income, outpacing the S&P 500. The key question is whether the distribution ... SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) plans to present extensive new clinical data at the 2026 ASCO Annual Meeting. The company will share more than 60 scientific disclosures, including 19 oral presentations across oncology programs. Late-breaking Phase 3 data, including SUCCESSOR-2 for mezigdomide and izalontamab brengitecan, will be highlighted. The updates cover multiple myeloma, lymphoma, breast and lung cancers, and several emerging oncology mechanisms. For investors tracking NYSE:BMY, this...
With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The multiple myeloma market is evolving toward immunotherapy-dominated, multi-line treatment paradigms with strong growth driven by CAR-T and bispecific antibodies. Leading contenders advancing through the pipeline include AZD0120 [AstraZeneca (Gracell Biotechnologies)], VENCLEXTA (venetoclax, ABT199 and RG7601) [AbbVie and Roche (Genentech)], Anito-cel (CART-ddBCMA) [Arcellx/Gilead (Kite)], Etentamig (ABBV-383) (AbbVie/TeneoOne), Iberdomide (CC-220) [Bristol-Myers Squibb (Celgene)], BMS-986393
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BMY | -1.79% | -8.28% | +6.01% | +18.43% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -4.76% | -2.56% | +9.45% | +5.75% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 98.56M | $5.98B | 0.21% | Added+0.6% | 2026-03-31 |
| TwoSigma | quant | 11.54M | $699.60M | 0.56% | Added+147.4% | 2026-03-31 |
| FidelityFMR | fundamental | 10.67M | $647.20M | 0.03% | Added+4.1% | 2026-03-31 |
| Wellington | fundamental | 5.51M | $334.00M | 0.06% | Trimmed-20.4% | 2026-03-31 |
| RenTech | quant | 977.1K | $59.26M | 0.09% | Trimmed-58.5% | 2026-03-31 |
| Citadel | multi-strat | 531.2K | $32.22M | 0.04% | Trimmed-82.3% | 2026-03-31 |
| DEShaw | quant | 309.8K | $18.79M | 0.01% | Added+3.3% | 2026-03-31 |
| Bridgewater | macro | 241.7K | $14.66M | 0.07% | Trimmed-40.9% | 2026-03-31 |
| TRowePrice | fundamental | 10.25M | $621.68K | 0.07% | Added+49.0% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-05 | Lenkowsky Adam | EVP, Chief Commercial Officer | M Option exercise(deriv) | 1,373 | — | +$0 |
| 2026-05-05 | Lenkowsky Adam | EVP, Chief Commercial Officer | F Tax withholding | 599 | $58.22 | −$34.9K |
| 2026-05-05 | Lenkowsky Adam | EVP, Chief Commercial Officer | J Other acquisition | 203 | — | +$0 |
| 2026-05-05 | Lenkowsky Adam | EVP, Chief Commercial Officer | M Option exercise | 1,373 | — | +$0 |
| 2026-04-02 | Arduini Peter J | Director | A Grant / award(deriv) | 577 | $60.65 | +$35.0K |
| 2026-04-02 | McMullen Michael R. | Director | A Grant / award(deriv) | 577 | $60.65 | +$35.0K |
| 2026-04-02 | Rice Derica W | Director | A Grant / award(deriv) | 639 | $60.65 | +$38.8K |
| 2026-04-02 | Samuels Theodore R. II | Director | A Grant / award(deriv) | 845 | $60.65 | +$51.2K |
| 2026-04-02 | YALE PHYLLIS R | Director | A Grant / award(deriv) | 577 | $60.65 | +$35.0K |
| 2026-04-02 | Elkins David V | EVP, Chief Financial Officer | S Open-market sale | 4,481 | $62.05 | −$278.0K |
| 2026-04-02 | Elkins David V | EVP, Chief Financial Officer | S Open-market sale | 25,519 | $61.60 | −$1.57M |
| 2026-04-02 | Shanahan Karin | EVP, Chief Supply Chain & Ops | M Option exercise(deriv) | 3,307 | — | +$0 |
| 2026-04-02 | Shanahan Karin | EVP, Chief Supply Chain & Ops | F Tax withholding | 1,692 | $61.73 | −$104.4K |
| 2026-04-02 | Shanahan Karin | EVP, Chief Supply Chain & Ops | M Option exercise | 3,307 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | A Grant / award(deriv) | 52,898 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | A Grant / award(deriv) | 35,265 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | M Option exercise(deriv) | 47,424 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | M Option exercise(deriv) | 7,904 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | M Option exercise(deriv) | 7,654 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | F Tax withholding | 10,240 | $60.13 | −$615.7K |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | J Other acquisition | 23,285 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | M Option exercise | 47,424 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | F Tax withholding | 2,991 | $60.13 | −$179.8K |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | J Other acquisition | 854 | — | +$0 |
| 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | M Option exercise | 7,904 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 1.61 | — | — |
| 2026-04-30 | 1.42 | 1.58 | +11.18% |
| 2026-02-05 | 1.20 | 1.26 | +4.57% |
| 2025-10-30 | 1.04 | 1.08 | +3.44% |
| 2025-07-31 | 0.67 | 0.64 | -3.80% |
| 2025-04-24 | 1.50 | 1.80 | +19.88% |
| 2025-02-06 | 1.47 | 1.67 | +13.80% |
| 2024-10-31 | 1.50 | 1.80 | +19.98% |
| 2024-07-26 | 1.63 | 2.07 | +27.37% |
| 2024-04-25 | -4.40 | -4.40 | -0.05% |
| 2024-02-02 | 1.58 | 1.70 | +7.77% |
| 2023-10-26 | 1.77 | 2.00 | +13.02% |
| 2023-07-27 | 1.99 | 1.75 | -11.98% |
| 2023-04-27 | 1.97 | 2.05 | +3.87% |
| 2023-02-02 | 1.73 | 1.82 | +5.17% |
| 2022-10-25 | 1.83 | 1.99 | +8.46% |